08:09 AM EST, 11/29/2024 (MT Newswires) -- Astrazeneca ( AZN ) confirmed Friday in an emailed statement to MT Newswires that its breast cancer treatment Enhertu and cancer treatment Orpathys have been added to China's National Reimbursement Drug List (NRDL)

The inclusion in the NRDL grants state-run medical insurance coverage to the cancer treatments, starting Jan. 1, 2025, multiple media outlets reported Thursday.

Enhertu is among 91 drugs that will be added to the NRDL, including oncology drugs from drugmakers including Johnson & Johnson ( JNJ ) , Merck ( MRK ) , Bristol Myers (BMY), Roche and Sanofi ( SNY ) , Bloomberg said and added that drugmakers have to accept price cuts, averaging 63%, to secure inclusion on the list.

Zai Lab ( ZLAB ) said Thursday its AUGTYRO was also included in the NRDL to treat adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer.